e-drug; Fighting poor-quality medicines in LMICs: the importance of advocacy
----------------------------------------------------------------------------------------------
Advocacy and pedagogy to fight poor-quality medicines in LMICs will be greatly supported if there is active reporting and testing of apparently poor-quality products.
In our recent opinion piece my co-authors and I stressed in a key point that 'The primary focus of Pacific Island pharmacovigilance should be on medicine quality.'
McEwen J, Vestergaard LS, Sanburg ALC. Pacific Island Pharmacovigilance:The Need for a Different Approach. Drug Safety. 2016; 39 (10): 891-894
submitted by John McEwen
former TGA Medical Advisor
mcewenj@iinet.net.au]
[details added by moderator]